Vitreofoveal Traction Associated With Pilocarpine for Presbyopia

Vuity (pilocarpine HCL ophthalmic 1.25%) was approved for the treatment of presbyopia in Oc-tober 2021. Previous case series have reported the presence of vitreofoveal traction and retinal detach-ment following pilocarpine administration, but this was not reported in the recent randomized control trials assessing the efficacy of Vuity. The authors re-port a case of a woman of 65 years who developed vitreomacular traction immediately following the first administration of Vuity, review the literature, and present considerations regarding screening and management of patients starting Vuity. [Ophthalmic Surg Lasers Imaging Retina 2022; 53:410-411.]

Automated summary

Vuity (pilocarpine HCL ophthalmic 1.25%) has been approved for treating presbyopia in October 2021. Previous case series reported vitreofoveal traction and retinal detachment after pilocarpine administration, but recent randomized control trials did not report such cases when evaluating the efficacy of Vuity. The authors present a case of vitreomacular traction observed immediately after the first administration of Vuity in a 65-year-old woman, review the literature, and discuss considerations for screening and managing patients starting Vuity. [Ophthalmic Surg Lasers Imaging Retina 2022; 53:410-411.]